Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Trial Profile

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Antithymocyte globulin; Bendamustine; Filgrastim; Fludarabine; Methotrexate; Rituximab; Tacrolimus
  • Indications Graft-versus-host disease; Leukaemia; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 31 Oct 2012 New source identified and integrated (M.D. Anderson Cancer Center).
    • 29 Oct 2012 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top